11th Advanced Forum on

Structuring, Negotiating and Managing Pharma/Biotech Collaborative Agreements

Wednesday, November 12, 2008

About

With pipelines drying up, patent expirations at an all time high and R&D costs through the roof, the stakes in negotiating and maintaining lucrative licensing and collaborations could not be higher. But as the critical nature of these deals increases, so do the challenges and complexities. Competition is increasing, laws are changing, and M&A activity is heating up. Further, IP valuation contingencies are arising in the wake of the Supreme Court's MedImmune decision, and parties are seeking greater protection for their IP rights and looking to draft termination provisions that allow both parties to walk away with their assets intact.

In addition, selecting the right partners, deal structure and compensation analysis are crucial to the success of the deal, and an assessment of these factors must be done early in the process. Lastly, as biotech/pharma look more and more to collaborate with the government and institutional researchers for a competitive edge, they face a distinct culture clash that leads to wheel-spinning, preventing agreements from being reached.

Unlike any other licensing event, you will not only get the opportunity to network with and learn from a diverse, front-line faculty of experienced in-house counsel, licensing and business development executives from leading pharmaceutical and biotech companies, but you will also receive practical guidance on how to translate new laws and trends into a winning business strategy and overcome challenges and complexities in negotiating and maintaining the best deal available for your company's needs.

American Conference Institute's annual conference continues its tradition this year by bringing together key industry leaders and government representatives in order to discuss the critical issues impacting this ever changing landscape. The conference program is currently under development but please check back soon for an updated agenda and list of keynote speakers.

Contents & Contributors

About

With pipelines drying up, patent expirations at an all time high and R&D costs through the roof, the stakes in negotiating and maintaining lucrative licensing and collaborations could not be higher. But as the critical nature of these deals increases, so do the challenges and complexities. Competition is increasing, laws are changing, and M&A activity is heating up. Further, IP valuation contingencies are arising in the wake of the Supreme Court's MedImmune decision, and parties are seeking greater protection for their IP rights and looking to draft termination provisions that allow both parties to walk away with their assets intact.

In addition, selecting the right partners, deal structure and compensation analysis are crucial to the success of the deal, and an assessment of these factors must be done early in the process. Lastly, as biotech/pharma look more and more to collaborate with the government and institutional researchers for a competitive edge, they face a distinct culture clash that leads to wheel-spinning, preventing agreements from being reached.

Unlike any other licensing event, you will not only get the opportunity to network with and learn from a diverse, front-line faculty of experienced in-house counsel, licensing and business development executives from leading pharmaceutical and biotech companies, but you will also receive practical guidance on how to translate new laws and trends into a winning business strategy and overcome challenges and complexities in negotiating and maintaining the best deal available for your company's needs.

American Conference Institute's annual conference continues its tradition this year by bringing together key industry leaders and government representatives in order to discuss the critical issues impacting this ever changing landscape. The conference program is currently under development but please check back soon for an updated agenda and list of keynote speakers.

Contents & Contributors

Factoring Takeaways from Recent Deals and Trends into Your Collaborations Strategy
Michael Crowley, Associate Director, Business Development, Genentech Inc. (South San Francisco, CA)
Denise M. McGinn, V.P., Business Development, Biotechnology, Immunology, Oncology, Johnson & Johnson Pharmaceuticals Group (Horsham, PA)
Alex Scott, Vice President, Business DevelopmentEisai (Woodcliff Lake, NJ)
Moderator:
Randall B. Sunberg, Partner, Chair Life Sciences Transactions, Morgan, Lewis & Bockius LLP (Princeton, NJ)

Limiting the Potential for Litigation: Best Drafting Practices After Quantaand MedImmune
Michael A. Epstein, Partner, Weil, Gotshal & Manges LLP (New York, NY)
Michael F. Hurley, Partner, McDermott Will & Emery LLP (New York, NY)

Prelude to Acquisition? Incorporating M & A Considerations Into Your Collaboration Strategy
Lawrence R. Miller, Assistant General Counsel, Licensing and Mergers & Acquisitions, Pfizer Inc. (New York, NY)
Faye H. Russell, Partner, Latham & Watkins LLP (San Diego, CA)
Kevin G. Taylor, Vice President of Business Development, Adolor Corporation (Exton, PA)

Negotiating Critical IP Terms and Compensation Structures to Accelerate Development and Maximize Profits
Timothy Herpin, Ph.D., Director, Scientific Licensing, Bristol-Myers Squibb (Princeton, NJ)
Fernando J. Salles, Ph.D., Senior Director, Global Strategy & Portfolio Management, Organon International, a part of Schering-Plough (Roseland, NJ)
Howard S. Schwartz, Partner, DLA Piper (Baltimore, MD)

Incorporating International Business Strategies into Collaborative Agreements
Eileen Smith Ewing, Partner, K&L Gates LLP (Boston, MA)
Kenneth Krisko, Partner, Cooley Godward Kronish LLP (Reston, VA)

Successfully Negotiating Collaborative Research Agreements with Academic Institutions
Nicholas Buffinger, Ph.D., Director, Strategic Alliances - Biologics, Novartis Institutes for BioMedical Research Inc.(Cambridge, MA)
John W. Puziss, Director of Technology Licensing, Yale University (New Haven, CT)
Catherine Shea, Associate Counsel for Technology Transfer and Research Compliance, University of Colorado (Denver, CO)

Alliance Management: Establishing Governance Structures for Successful Collaborations
Paul A. Stewart, Manager, Global Business Development, Eli Lilly (Indianapolis, IN)
Brianne Weingarten, Executive Director, Alliance Management, Purdue Pharma (Stamford, CT)
Frank S. Vellucci, Partner, Chadbourne & Parke LLP (New York, NY)

Asset Spin-Outs: Overcoming Challenges in Negotiating Out Licensing by Pharma and Big Biotech
Cynthia J. Zarsky, Senior Director, Research Contracts and Outlicensing Merck Research Laboratories (Rahway, NJ)
Kingsley L. Taft, Ph.D., Partner, Goodwin Proctor LLP (Boston, MA)

Setting the Stage for Success by Choosing the Right Partner and Conducting Effective Due Diligence
Paul Thompson, Senior Legal Director, Licensing, Schering-Plough (Kenilworth, NJ)
Beth E. Arnold, Partner, Foley Hoag LLP (Boston, MA)

Defining Critical Termination Rights
Alane Barnes, General Counsel, BioCryst Pharmaceuticals, Inc. (Birmingham, AL)
Daryn A. Grossman, Partner, Proskauer Rose LLP (New York, NY)



DOCUMENT TYPES: PPT PPTX PDF PRESENTATIONS AVAILABLE: 18

7:30
Registration and Continental Breakfast
8:30
Co-Chairs' Opening Remarks
Mr. John Hurvitz
Partner
Covington & Burling LLP
Mr. William F. Mongan
Executive Director of U.S. Business Development
AstraZeneca LP
8:45
Factoring Takeaways from Recent Deals and Trends into Your Collaborations Strategy
Mr. Michael Crowley
Associate Director Business Development
Genentech
Ms. Denise McGinn
Vice President‚ Business Development
Johnson & Johnson Pharmaceuticals Group
Mr. Alex Scott
Vice President Business Development
Eisai Inc.
Mr. Randall Sunberg
Partner and Chair Life Sciences Transactions
Morgan‚ Lewis & Bockius LLP
1 file
Crowley.M.McGinn.D.Scott.A.Sunberg.R
1.3 MB 3 pages Presentation
PPT - Crowley.M.McGinn.D.Scott.A.Sunberg.R
10:00
Morning Coffee Break
10:15
Limiting the Potential for Litigation: Best Drafting Practices After Quanta and MedImmune
Mr. Michael J. Epstein
Managing Partner
CRG Partners Group LLC
1 file
Epstein.M
505 KB 19 pages Presentation
PPT - Epstein.M
Mr. Michael Hurley
Partner
McDermott Will & Emery LLP
1 file
Hurley.M
653 KB 26 pages Presentation
PPT - Hurley.M
11:15
Prelude to Acquisition? Incorporating M & A Considerations Into Your Collaboration Strategy
Mr. Lawrence R. Miller
Assistant General Counsel
Pfizer
Ms. Faye Russell
Partner
Latham & Watkins
Mr. Kevin Taylor
Vice President Business Development
Adolor Corporation
1 file
Miller.LTaylor.K.Russell.F
349.5 KB 35 pages Presentation
PPT - Miller.LTaylor.K.Russell.F
12:30
Networking Luncheon for Speakers and Delegates
13:45
Negotiating Critical IP Terms and Compensation Structures to Accelerate Development and Maximize Profits
Mr. Timothy E. Herpin
Director‚ Scientific Licensing
Bristol-Meyers Squibb
Dr. Fernando Salles
Senior Director
Merck & Co.‚ Inc.
Mr. Howard S. Schwartz
Partner
DLA Piper
1 file
Schwartz.H
3 MB 9 pages Presentation
PPT - Schwartz.H
15:15
Afternoon Refreshment Break
15:30
Incorporating International Business Strategies into Collaborative Agreements
- Ms. Eileen Smith Ewing
Partner
K&L Gates
1 file
EileenSmith.Ewing
240 KB 6 pages Presentation
PPT - EileenSmith.Ewing
Mr. Kenneth Krisko
Partner
Cooley Godward
1 file
Krisko.K
140 KB 8 pages Presentation
PPT - Krisko.K
Mr. Ira A. Schreger
Partner
Loeb & Loeb LLP
1 file
Schreger
1.5 MB 1 page Presentation
PPT - Schreger
16:45
Join the speakers and your peers to continue the day's discussions over cocktails.
17:15
Conference Adjourns
7:30
Registration and Continental Breakfast
8:15
Co-Chairs' Remarks
Mr. John Hurvitz
Partner
Covington & Burling LLP
Mr. William F. Mongan
Executive Director of U.S. Business Development
AstraZeneca LP
8:30
Successfully Negotiating Collaborative Research Agreements with Academic Institutions
Nicholas Buffinger, Ph.D.
Director‚ Strategic Alliances - Biologics
Novartis Institutes for BioMedical Research‚ Inc.
1 file
Nicholas.Buffinger
213 KB 7 pages Presentation
PPT - Nicholas.Buffinger
Mr. John W. Puziss
Director of Technology Licensing
Yale University
1 file
Puziss.J
194.5 KB 8 pages Presentation
PPT - Puziss.J
Ms. Catherine Shea
Associate Counsel for Technology Transfer
University of Colorado
1 file
Shea.C
1.4 MB 12 pages Presentation
PPTX - Shea.C
Dr. Ofra Weinberger
Director‚ Health Sciences‚ Science and Technology Ventures
Columbia University
1 file
Ofra.Weinberger
192 KB 10 pages Presentation
PPT - Ofra.Weinberger
Ms. Emily I. Leonard
Partner
Covington & Burling LLP
9:45
Morning Coffee Break
10:00
Alliance Management: Establishing Governance Structures for Successful Collaborations
Paul A. Stewart
Manager‚ Global Business Development
Eli Lilly
1 file
Stewart.P
1.8 MB 28 pages Presentation
PDF - Stewart.P
Ms. Brianne Weingarten
Executive Director‚ Alliance Management
Purdue Pharma
1 file
Weingarten.B
249.5 KB 21 pages Presentation
PPT - Weingarten.B
11:15
Asset Spin-Outs: Overcoming Challenges in Negotiating Out Licensing by Pharma and Big Biotech
Ms. Cynthia Zarsky
Senior Director‚ Research Contracts & Outlicensing
Merck
1 file
Zarsky.C
72.4 KB 10 pages Presentation
PDF - Zarsky.C
Mr. Kingsley L. Taft
Partner
Goodwin Procter LLP
1 file
Kingsley.Taft
240.5 KB 24 pages Presentation
PPT - Kingsley.Taft
12:00
Networking Luncheon for Speakers and Delegates
13:15
Setting the Stage for Success by Choosing the Right Partner and Conducting Effective Due Diligence
Mr. Paul Thompson
Senior Legal Director‚ Licensing
Schering Plough Corporation
Ms. Beth E. Arnold
Partner
Foley Hoag LLP
1 file
Arnold.B
380.5 KB 13 pages Presentation
PPT - Arnold.B
14:15
Defining Critical Termination Rights
Ms. Alane Barnes
General Counsel
BioCryst Pharmaceutical Inc.
Ms. Daryn Grossman
Partner and Co-Chair‚ Life Sciences Practice
Proskauer Rose LLP
1 file
Barnes.A.Grossman.D
695.5 KB 18 pages Presentation
PPT - Barnes.A.Grossman.D
15:00
Conference Concludes